These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 16624468

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Switching among antipsychotics in everyday clinical practice: focus on ziprasidone.
    Rossi A, Cañas F, Fagiolini A, Larmo I, Levy P, Montes JM, Papageorgiou G, Sturlason R, Zink M, Correll CU.
    Postgrad Med; 2011 Jan; 123(1):135-59. PubMed ID: 21293094
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Ziprasidone-induced galactorrhea: a case report.
    Kopecek M, Bares M, Mohr P.
    Neuro Endocrinol Lett; 2005 Feb; 26(1):69-70. PubMed ID: 15726024
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The effectiveness of ziprasidone in treating impaired quality of life in schizophrenia: a 12-month, open-label, flexible-dose, naturalistic observational study of patients undergoing usual care.
    Ritsner MS, Yorkov V, Ratner Y, Soifer P, Gibel A.
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct 01; 31(7):1470-7. PubMed ID: 17669573
    [Abstract] [Full Text] [Related]

  • 13. A 6-month prospective, observational, naturalistic, uncontrolled study to evaluate the effectiveness and tolerability of oral ziprasidone in patients with schizophrenia.
    Arango C, Gómez-Beneyto M, Brenlla J, Gastó C, Sarramea-Crespo F, Chamorro L, Masramon X, Díez T, ZIS Study Group.
    Eur Neuropsychopharmacol; 2007 Oct 01; 17(6-7):456-63. PubMed ID: 17234389
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.
    Cutler AJ, Kalali AH, Weiden PJ, Hamilton J, Wolfgang CD.
    J Clin Psychopharmacol; 2008 Apr 01; 28(2 Suppl 1):S20-8. PubMed ID: 18334909
    [Abstract] [Full Text] [Related]

  • 18. Ziprasidone-associated depressive state in schizophrenic patients.
    Kaptsan A, Dwolatzky T, Lerner V.
    Clin Neuropharmacol; 2007 Apr 01; 30(6):357-61. PubMed ID: 18090461
    [Abstract] [Full Text] [Related]

  • 19. Probable association between ziprasidone and worsening hypertension.
    Villanueva N, Markham-Abedi C, McNeely C, Diaz FJ, de Leon J.
    Pharmacotherapy; 2006 Sep 01; 26(9):1352-7. PubMed ID: 16945059
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.